p-CH3C6H4MgBr

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-CH3C6H4MgBr
• 化学式: C₇H₇BrMg
• 分子量: 195.342
• InChiKey: UYODFRPEMVNBNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  p-CH3C6H4MgBr 在 HgCl₂ 、 KI 作用下， 以 乙醚 为溶剂， 生成
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Cr: Org.Verb., 1.6.2.1.3, page 348 - 352

  摘要：

  DOI：

文献信息

• Use of ER selective NF-kB inhibitors for the treatment of sepsis
  申请人：Caggiano J. Thomas

  公开号：US20050256132A1

  公开（公告）日：2005-11-17

  The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:

  本发明提供了通过调节与雌激素受体相互作用的配体来调节NF-κB转录，从而治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，优选在无典型雌激素活性的情况下进行。本发明的其他方面涉及治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，包括向患有此类病症的患者施用有效量的式I化合物：
• [EN] (DIARYL-METHYL)-MALONONITRILES AND THEIR USE AS ESTROGEN RECEPTOR LIGANDS<br/>[FR] (DIARYL-METHYL)-MALONONITRILES ET LEUR UTILISATION EN TANT QUE LIGANDS DU RECEPTEUR D'OESTROGENE
  申请人：WYETH CORP

  公开号：WO2005121076A1

  公开（公告）日：2005-12-22

  The present invention concerns compounds of formula (I) where R1, R2, R3 and R4 are defined in the specification.

  本发明涉及式（I）化合物，其中R1、R2、R3和R4在规范中有定义。
• [EN] NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY<br/>[FR] MODULATEURS DES RÉCEPTEURS GLUCOCORTICOÏDES NON STÉROÏDIENS POUR ADMINISTRATION LOCALE DE MÉDICAMENTS
  申请人：LEO PHARMA AS

  公开号：WO2017046096A1

  公开（公告）日：2017-03-23

  The present invention relates to a compound according to formula (I) wherein R1 is selected from the group consisting of 5- and 6- membered heteroaryl, (C1- C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl; R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R4 is selected from hydrogen, halogen, (C1- C4)alkyl and halo(C1-C4)alkyl; X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N; Y is selected from -NH- and -O-; m is 0 or 1; n is 0 or 1; L represents a bond, -O-, -NH- or -N(RC)-; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种化合物，其化学式为(I)，其中R1选自由5-和6-成员杂芳基、(C1-C6)烷基、(C3-C6)环烷基、(4-6)-成员杂环烷基和苯基；R2选自(C1-C3)烷基和卤代(C1-C3)烷基；R3选自苯基、5-成员杂芳基和6-成员杂芳基；R4选自氢、卤素、(C1-C4)烷基和卤代(C1-C4)烷基；X1选自CH、C(Rb)和N，X2选自CH和N；Y选自-NH-和-O-；m为0或1；n为0或1；L代表键，-O-，-NH-或-N(RC)-；或其药学上可接受的盐、水合物或溶剂化合物。本发明还涉及用于制备所述化合物的中间体，用于治疗的该化合物，包含该化合物的药物组合物，使用该化合物治疗疾病的方法，以及使用该化合物制造药品的用途。
• Novel Transition Metal Compound and Method for Preparing the Same
  申请人：LG Chem, Ltd.

  公开号：US20210032274A1

  公开（公告）日：2021-02-04

  A transition metal compound represented by Chemical Formula I and a method for preparing the same, catalyst compositions including the same, and olefin-based polymers prepared from the same are disclosed herein. The transition metal catalyst has excellent structural stability together with excellent catalytic activity and can exhibit excellent copolymerizability even at a high temperature. In an embodiment, an olefin-based polymer prepared using a catalyst composition including the transition metal compound has a density of 0.91 g/cc or less.

  本文揭示了一种由化学式I表示的过渡金属化合物，以及制备该化合物的方法，包括该化合物的催化剂组合物和由该化合物制备的基于烯烃的聚合物。过渡金属催化剂具有优异的结构稳定性和优异的催化活性，即使在高温下也能展现出优异的共聚性。在一个实施例中，使用包含过渡金属化合物的催化剂组合物制备的基于烯烃的聚合物的密度为0.91g/cc或更低。
• 7-Substituted camptothecin and camptothecin analogs and methods for producing the same
  申请人：Research Triangle Insitute

  公开号：US20040266803A1

  公开（公告）日：2004-12-30

  Methods of forming camptothecin compounds which are effective anti-tumor compounds are disclosed. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex.

  揭示了形成有效的抗肿瘤化合物喜树碱的方法。这些化合物抑制酶拓扑异构酶I，并可能烷基化与拓扑异构酶I-DNA可断裂复合物相关的DNA。